Medulloblastoma-Pipeline Review, H2 2017

Medulloblastoma-Pipeline Review, H2 2017


  • Products Id :- GMDHC10014IDB
  • |
  • Pages: 197
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Medulloblastoma-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma-Pipeline Review, H2 2017, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 8, 3 and 15 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Medulloblastoma-Overview

Medulloblastoma-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Medulloblastoma-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Medulloblastoma-Companies Involved in Therapeutics Development

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Janpix Inc

Lipocure Ltd

MacroGenics Inc

Medicenna Therapeutics Corp

Millennium Pharmaceuticals Inc

NewLink Genetics Corp

Ono Pharmaceutical Co Ltd

Progenics Pharmaceuticals Inc

Stemline Therapeutics Inc

ThromboGenics NV

VBI Vaccines Inc

Vyriad Inc

Medulloblastoma-Drug Profiles

(topotecan hydrochloride + vincristine sulfate)-Drug Profile

afatinib dimaleate-Drug Profile

Bispecific Monoclonal Antibodies to Target IL13RA2 and CD3 for Oncology-Drug Profile

Bispecific Monoclonal Antibodies to Target ROR1 and CD3 for Oncology-Drug Profile 50

Cellular Immunotherapy for Oncology-Drug Profile

dianhydrogalactitol-Drug Profile

Edotreotide Labeled Yttrium 90-Drug Profile 70

IMP-5471-Drug Profile

indoximod-Drug Profile

ipilimumab + nivolumab-Drug Profile 80

irinotecan hydrochloride + TBio-02-Drug Profile 90

LY-5-Drug Profile

MDNA-55-Drug Profile

nifurtimox-Drug Profile

nivolumab-Drug Profile

Oncolytic Virus to Target CD46 and SLC5A5 for Brain Tumor and Recurrent Medulloblastoma-Drug Profile

p28-Drug Profile

pomalidomide-Drug Profile

pyrvinium pamoate-Drug Profile

sapanisertib-Drug Profile

SL-301-Drug Profile

Small Molecule to Antagonize Smoothened Homolog for Medulloblastoma and Colon Cancer-Drug Profile

Small Molecules to Inhibit STAT3 and STAT5 for Oncology-Drug Profile 170

Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme-Drug Profile

Small Molecules to Inhibit STAT5 for Oncology-Drug Profile

taladegib-Drug Profile

THR-317-Drug Profile

Trilexium-Drug Profile

Vaccine to Target CMV Antigen for Central Nervous System Cancer-Drug Profile

VBI-1901-Drug Profile

VMY-1103-Drug Profile

Medulloblastoma-Dormant Projects

Medulloblastoma-Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Medulloblastoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Medulloblastoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Medulloblastoma-Pipeline by Bayer AG, H2 2017

Medulloblastoma-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Medulloblastoma-Pipeline by Bristol-Myers Squibb Co, H2 2017

Medulloblastoma-Pipeline by Celgene Corp, H2 2017

Medulloblastoma-Pipeline by DelMar Pharmaceuticals Inc, H2 2017

Medulloblastoma-Pipeline by Ignyta Inc, H2 2017

Medulloblastoma-Pipeline by IMPACT Therapeutics Inc, H2 2017

Medulloblastoma-Pipeline by Janpix Inc, H2 2017

Medulloblastoma-Pipeline by Lipocure Ltd, H2 2017

Medulloblastoma-Pipeline by MacroGenics Inc, H2 2017

Medulloblastoma-Pipeline by Medicenna Therapeutics Corp, H2 2017

Medulloblastoma-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Medulloblastoma-Pipeline by NewLink Genetics Corp, H2 2017

Medulloblastoma-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Medulloblastoma-Pipeline by Progenics Pharmaceuticals Inc, H2 2017

Medulloblastoma-Pipeline by Stemline Therapeutics Inc, H2 2017

Medulloblastoma-Pipeline by ThromboGenics NV, H2 2017

Medulloblastoma-Pipeline by VBI Vaccines Inc, H2 2017

Medulloblastoma-Pipeline by Vyriad Inc, H2 2017

Medulloblastoma-Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Janpix Inc

Lipocure Ltd

MacroGenics Inc

Medicenna Therapeutics Corp

Millennium Pharmaceuticals Inc

NewLink Genetics Corp

Ono Pharmaceutical Co Ltd

Progenics Pharmaceuticals Inc

Stemline Therapeutics Inc

ThromboGenics NV

VBI Vaccines Inc

Vyriad Inc

select a license
Single User License
USD 2000 INR 137580
Site License
USD 4000 INR 275160
Corporate User License
USD 6000 INR 412740

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com